{"filing":{"accession_number":"0001437749-26-025074","cik":"0001595248","ticker":"GNPX","company_name":"Genprex, Inc.","form":"8-K","filing_date":"2026-07-30","report_date":"2026-07-29","primary_document":"gnpx20260730_8k.htm","primary_document_url":"https://www.sec.gov/Archives/edgar/data/1595248/000143774926025074/gnpx20260730_8k.htm"},"events":[{"id":22232,"run_id":20101,"accession_number":"0001437749-26-025074","anchor_item_number":"3.01","event_type":"delisting_risk","event_domain":"terminal","is_material":true,"confidence":0.95,"summary":"Genprex received a Nasdaq delisting notice on June 10, 2026 for failure to maintain the $1.00 minimum bid price requirement. Although the Nasdaq Hearings Panel granted an exception on July 29, 2026 allowing continued listing through December 7, 2026 subject to strict conditions, the company faces material delisting risk if it fails to maintain compliance with the bid price requirement during this cure period.","company_name":"Genprex, Inc.","ticker":"GNPX","filing_date":"2026-07-30","form":"8-K","submitted_at":null,"items":[{"id":22114,"accession_number":"0001437749-26-025074","item_number":"3.01","item_title":"Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing.","event_type":"delisting_risk","event_domain":"terminal","is_material":true,"confidence":0.95,"reasoning":"The filing discloses a notice of delisting risk under Item 3.01. Genprex received a June 10, 2026 Nasdaq delisting notice for failure to maintain the $1.00 Minimum Bid Price requirement and was ineligible for the standard 180-day cure period. Although the Nasdaq Hearings Panel granted an exception on July 29, 2026 allowing continued listing subject to strict conditions (maintaining $1.00 bid price through December 7, 2026 with Panel jurisdiction), the disclosure explicitly states \"There can be no assurance that the Company will be able to satisfy the terms of the Exception\" and reserves the Panel's right to reconsider based on future events. This is a material delisting risk event that would significantly affect investor assessment of the registrant's continued exchange listing.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-07-31T00:18:23.455772+00:00","company_name":"","ticker":null,"filing_date":""},{"id":22115,"accession_number":"0001437749-26-025074","item_number":"8.01","item_title":"Other Events.","event_type":"delisting_risk","event_domain":"terminal","is_material":true,"confidence":0.95,"reasoning":"Genprex received a delisting notice from Nasdaq on June 10, 2026 for failing to maintain the $1.00 minimum bid price requirement. Although the company obtained a hearing and the Nasdaq Panel granted an exception on July 29, 2026 allowing until December 7, 2026 to demonstrate compliance, the filing explicitly discloses the delisting risk and the conditions under which delisting could occur. The disclosure details the company's reverse stock split implementation and the material adverse consequences of potential delisting, making this a clear delisting_risk event.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-07-31T00:18:23.455772+00:00","company_name":"","ticker":null,"filing_date":""}]}],"classifications":[{"id":22114,"accession_number":"0001437749-26-025074","item_number":"3.01","item_title":"Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing.","event_type":"delisting_risk","event_domain":"terminal","is_material":true,"confidence":0.95,"reasoning":"The filing discloses a notice of delisting risk under Item 3.01. Genprex received a June 10, 2026 Nasdaq delisting notice for failure to maintain the $1.00 Minimum Bid Price requirement and was ineligible for the standard 180-day cure period. Although the Nasdaq Hearings Panel granted an exception on July 29, 2026 allowing continued listing subject to strict conditions (maintaining $1.00 bid price through December 7, 2026 with Panel jurisdiction), the disclosure explicitly states \"There can be no assurance that the Company will be able to satisfy the terms of the Exception\" and reserves the Panel's right to reconsider based on future events. This is a material delisting risk event that would significantly affect investor assessment of the registrant's continued exchange listing.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-07-31T00:18:23.455772+00:00","company_name":"Genprex, Inc.","ticker":"GNPX","filing_date":"2026-07-30"},{"id":22115,"accession_number":"0001437749-26-025074","item_number":"8.01","item_title":"Other Events.","event_type":"delisting_risk","event_domain":"terminal","is_material":true,"confidence":0.95,"reasoning":"Genprex received a delisting notice from Nasdaq on June 10, 2026 for failing to maintain the $1.00 minimum bid price requirement. Although the company obtained a hearing and the Nasdaq Panel granted an exception on July 29, 2026 allowing until December 7, 2026 to demonstrate compliance, the filing explicitly discloses the delisting risk and the conditions under which delisting could occur. The disclosure details the company's reverse stock split implementation and the material adverse consequences of potential delisting, making this a clear delisting_risk event.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-07-31T00:18:23.455772+00:00","company_name":"Genprex, Inc.","ticker":"GNPX","filing_date":"2026-07-30"}]}